Why the study?
Numerous transcatheter therapies have emerged for high surgical risk patients with severe mitral regurgitation, warranting an overview of these technologies and their potential complications.
This clinical update provides an overview of current percutaneous mitral valve repair technologies and highlights their potential complications in high-surgical-risk patients.
Answers are grounded in this paper and cite their sources.
Complication rates in early MitraClip experience warrant caution in high-risk cases; leaves open safety optimization for newer devices.
Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.
No takes yet. Share an insight, caveat, or question.
Gheorghe et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: